Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | AOC2 | O75106 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25904114 | 0.90 | SIGMAR1 (0.37) | CHRM2CHRM1CHRM3ACHEGNAI3 | |
| SCHEMBL25917024 | 0.86 | ACHE (0.37) | CHRM2CHRM1CHRM3ACHEGNAI3 | |
| SCHEMBL25904125 | 0.86 | CXCR3 (0.34) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| SCHEMBL25916762 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1CHRM3ACHEGNAI3 | |
| SCHEMBL25904071 | 0.77 | CXCR3 (0.38) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| SCHEMBL15945549 | 0.77 | THRA (0.42) | CHRM2CHRM1CHRM3CXCR3AOC2 | |
| SCHEMBL18997472 | 0.75 | GNAI3 (0.43) | GNAI3GNAO1GNAI1CXCR3AOC2 | |
| SCHEMBL27270298 | 0.75 | CXCR3 (0.37) | GNAI3GNAO1GNAI1CXCR3AOC2 | |
| SCHEMBL25904097 | 0.74 | ITGB3 (0.40) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| SCHEMBL3119356 | 0.74 | ALDH1A1 (0.39) | CHRM2CHRM1CHRM3GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | CHRM2 4829/4885CHRM1 4841/4885CHRM3 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.